Clinical Trials Sponsored by Noho Health

Total 51760 results

Novo Nordisk A/S

Completed

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

Obesity | Metabolism and Nutrition Disorder

Denmark
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Poland, Slovakia, Czechia
Novo Nordisk A/S

Completed

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Diabetes Mellitus, Type 2 | Diabetes

Italy
Novo Nordisk A/S

Completed

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Austria, Norway, Algeria
Novo Nordisk A/S

Completed

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes (DUAL™ I)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Russian Federation, Slovakia, Spain, Canada, Taiwan, Finland, Hungary, Malaysia, South Africa, United Kingdom, Germany, Australia, Thailand, Ireland, Puerto Rico, Singapore
Novo Nordisk A/S

Completed

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (mentor™2)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

France, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes (onset® 4)

Diabetes | Diabetes Mellitus, Type 1

United States, Germany
Novo Nordisk A/S

Completed

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Italy, United Kingdom, France, Serbia, Germany, South Africa, Canada, Ukraine, United Arab Emirates
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes (LIRA-Ramadan™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Malaysia, South Africa, Algeria, Lebanon, United Arab Emirates
Novo Nordisk A/S

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Terminated

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

Obesity | Metabolism and Nutrition Disorder

Netherlands
Novo Nordisk A/S

Completed

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Austria, Spain, Poland, United Kingdom, Croatia, Germany, Malaysia, Australia, France, Israel, Thailand, Ukraine, Turkey
Novo Nordisk A/S

Completed

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Diabetes Mellitus, Type 1

United Kingdom, Denmark, Sweden, Netherlands, Belgium, Finland, France, Australia, Ireland, Norway
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Congenital Bleeding Disorder | Glanzmann's Disease

Japan
Novo Nordisk A/S

Completed

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes (DIET™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Slovakia, Germany, Argentina, Serbia, Poland, Russian Federation, Slovenia, Spain, Turkey
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Inflammation | Crohn's Disease

United States, Spain, Bulgaria, Czech Republic, Poland, Slovakia
Novo Nordisk A/S

Terminated

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, United States, Switzerland, France, Germany, Canada
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BOOST™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico, Russian Federation, United Kingdom, Denmark, France, Israel, Australia, Romania
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)

Congenital Bleeding Disorder | Haemophilia A

United States, Macedonia, The Former Yugoslav Republic of, Serbia, Malaysia, Brazil, Turkey, Lithuania, Russian Federation, Italy, Japan, Poland, Puerto Rico, Taiwan
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of Levemir® in Diabetes (PREDICTIVE™)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Israel, Korea, Republic of, Turkey, Italy, Belgium, United Kingdom, Greece, Ireland, Sweden, Denmark, Finland, France, Czech Republic
Novo Nordisk A/S

Terminated

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Novo Nordisk A/S

Completed

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Korea, Republic of, China
Novo Nordisk A/S

Completed

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-6)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Denmark, Sweden, Austria, Germany, Macedonia, The Former Yugoslav Republic of, Slovenia, France, Switzerland, Norway, Spain, Ireland, Finland, Romania
Novo Nordisk A/S

Completed

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Puerto Rico, United Kingdom, Ireland, Germany, Slovenia, Canada, France, Italy, Spain, Netherlands, Slovakia, Romania, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Germany, Netherlands, Argentina, Finland, Serbia, Mexico
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Terminated

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c (LEAD-3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Mexico, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together (LEAD-2)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia, India, Italy, Russian Federation, Spain, Denmark, United Kingdom, Sweden, Belgium, Ireland, Argentina, Hungary, Norway, South Africa, Germany, Croatia, Netherlands, Bulgaria, Australia, Romania
Novo Nordisk A/S

Completed

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Finland, Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, United Kingdom, Ireland, France, South Africa, Ukraine

Clinical Trials Sponsored by Noho Health

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations